anti-B7-H3/topoisomerase-1 inhibitor antibody-drug conjugate BGB-C354
Term · Oncology and biomedicine · MLC-T-ONC-010141
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-B7-H3/topoisomerase-1 inhibitor ADC BGB-C354, the antibody moiety targets and binds to B7-H3-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing B7-H3. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation, and its overexpression plays a key role in tumor cell invasion and metastasis.
| Identifier | MLC-T-ONC-010141 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ADC BGB-C354; anti-B7-H3/topoisomerase-1 inhibitor ADC BGB-C354; Anti-CD276 ADC BGB-C354; antibody-drug conjugate BGB-C354 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010141",
"term": "anti-B7-H3/topoisomerase-1 inhibitor antibody-drug conjugate BGB-C354",
"field": "Oncology and biomedicine",
"definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-B7-H3/topoisomerase-1 inhibitor ADC BGB-C354, the antibody moiety targets and binds to B7-H3-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing B7-H3. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation, and its overexpression plays a key role in tumor cell invasion and metastasis.",
"synonyms": [
"ADC BGB-C354",
"anti-B7-H3/topoisomerase-1 inhibitor ADC BGB-C354",
"Anti-CD276 ADC BGB-C354",
"antibody-drug conjugate BGB-C354"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-b7-h3-topoisomerase-1-inhibitor-antibody-drug-conjugate-bgb-c354/"
}
Record 1,214 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.